Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > No link between brain tumours and ‘usual’ use of mobile phones
  • News

No link between brain tumours and ‘usual’ use of mobile phones

  • 14 April 2022
  • Janet Fricker
No link between brain tumours and ‘usual’ use of mobile phones
Total
0
Shares
0
0
0
0
0

‘Usual’ use of mobile phones does not increase the incidence of brain tumours. The prospective study, published in the Journal of the National Cancer Institute, 30 March 2022, found no statistically significant associations between ‘ever’ users and ‘never’ users of mobile phones for all brain tumours, and for the subtypes gliomas, meningiomas, pituitary tumours and acoustic neuromas.

“These results support the accumulating evidence that mobile phone use under usual conditions doesn’t increase brain tumour risk,” says co-investigator Kirstin Pirie, of the Cancer Epidemiology Unit at Oxford University’s Nuffield Department of Population Health.

Over the last few decades mobile phones have become an everyday device, with an estimated 8.65 billion users worldwide in 2021. To enable wireless communications, cellular phones emit radiofrequency electromagnetic fields (RF-EMFs). Since mobile phones are held close to the temporal and parietal lobes, concerns have been raised about RF-EMFs causing adverse biological effects to brain tissue. Most studies investigating connections between mobile phones and cancer have been retrospective, with participants reporting mobile phone use following a diagnosis of cancer, creating possibilities for bias. Ongoing debate around the carcinogenicity of RF-EMFs has recently been fuelled by two animal bioassays observing an increase in heart schwannoma.

In the current study, investigators from the Cancer Epidemiology Unit at the University of Oxford and the International Agency for Research on Cancer (IARC), France, reviewed data from the UK Million Women Study which had recruited one in four of all UK women born between 1935 and 1950. Around 776,000 participants completed questionnaires about mobile phone usage in 2001, with around half of these women surveyed again in 2011. Participants were then followed for an average of 14 years through linkage to NHS records, providing data on deaths and cancer registrations (including non-malignant brain tumours). Cox regression models were used to estimate the hazard ratios (referred to as relative risks) for outcomes of interest relating to mobile phone use.

Results showed that, over 14 years follow-up, 3,268 women (0.42%) developed a brain tumour. Relative risk (RR) for ‘ever’ versus ‘never’ cellular mobile phone use for all brain tumours was 0.97 (95%CI 0.90‒1.04), for glioma it was 0.89 (95%CI 0.80‒0.99), for glioblastoma 0.93 (95%CI 0.82–1.06), and for meningioma, pituitary tumours, acoustic neuroma and other tumours it was close to 1.

The incidence of right-sided and left-sided tumours were  similar in mobile phone users, even though mobile phone use tends to be considerably greater on the right side as opposed to left.

“In this large-scale prospective study of UK women, there was little to suggest that the use of cellular telephones increases the risk of brain tumours, overall or by subtype or by tumour location. This finding supports the accumulating evidence that cellular telephone use under usual conditions does not increase brain tumour risk,” conclude the authors. Future research, they add, should specifically target very heavy cellular telephone users, with attention to new features of a continuously evolving technology.

“Given the lack of evidence for heavy users, advising mobile phone users to reduce unnecessary exposures remains a good precautionary approach,” says lead investigator Joachim Schüz from IARC.

Such precautionary approaches, suggest the authors, include reducing exposure by using head phones or loudspeakers for calls of long durations.

In an accompanying editorial Douglas Weed, retired from the US National Cancer Institute, writes, “In sum, the results of this study push things a little closer to the consensus view on causation.”

The current results, Weed points out, contrast with an earlier analysis of the same cohort (published in 2013) which found long-term users versus never users  of mobile phones had increased risk of acoustic neuromas.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • acoustic neuroma
  • brain tumour
  • glioma
  • meningioma
  • mobile phone
  • pituitary tumour
  • radiofrequency electromagnetic fields
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Editorials

Pandemics, War, Reconstruction and the Duty of Medicine and Science

  • 4 April 2022
  • Adriana Albini
View Post
Next Article
  • Voices

Message from a Ukrainian oncologist: Please prioritise my patients ‒ if you don’t who will?

  • 19 April 2022
  • Mohammed Hojouj
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
  • AI application in diagnosis
    • 11 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.